PT  - JOURNAL ARTICLE
AU  - Kusec, Andrea
AU  - Milosevich, Elise
AU  - Williams, Owen A.
AU  - Chiu, Evangeline G.
AU  - Watson, Pippa
AU  - Carrick, Chloe
AU  - Drozdowska, Bogna A.
AU  - Dillon, Avril
AU  - Jennings, Trevor
AU  - Anderson, Bloo
AU  - Dawes, Helen
AU  - Thomas, Shirley
AU  - Kuppuswamy, Annapoorna
AU  - Pendlebury, Sarah T.
AU  - Quinn, Terence J.
AU  - Demeyere, Nele
TI  - Long-term psychological outcomes following stroke: The OX-CHRONIC study
AID  - 10.1101/2023.03.27.23287789
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.03.27.23287789
4099  - http://medrxiv.org/content/early/2023/05/22/2023.03.27.23287789.short
4100  - http://medrxiv.org/content/early/2023/05/22/2023.03.27.23287789.full
AB  - Background Stroke survivors rate longer-term (>2 years) psychological recovery as their top priority, but data on how frequently psychological consequences occur is lacking. Prevalence of cognitive impairment, depression/anxiety, fatigue, apathy and related psychological outcomes, and whether rates are stable in long-term stroke, is unknown.Methods N = 105 long-term stroke survivors (M [SD] age = 72.92 [13.01]; M [SD] acute NIH Stroke Severity Score = 7.39 [6.25]; 59.0% Male; M [SD] years post-stroke = 4.57 [2.12]) were recruited (potential N = 208). Participants completed 3 remote assessments, including a comprehensive neuropsychological battery, and questionnaires on emotional distress, fatigue, apathy and other psychological outcomes. Ninety participants were re-assessed one year later. Stability of outcomes was assessed by Cohen’s d effect size estimates and percent Minimal Clinically Important Difference changes between time points.Results On the Montreal Cognitive Assessment 65.3% scored <26. On the Oxford Cognitive Screen 45.9% had at least one cognitive impairment. Attention (27.1%) and executive function (40%) were most frequently impaired. 23.5% and 22.5% had elevated depression/anxiety respectively. Fatigue (51.4%) and apathy (40.5%) rates were high. Attention (d = −0.12; 85.8% stable) and depression (d = 0.09, 77.1% stable) were the most stable outcomes. Following alpha-adjustments, only perceptuomotor abilities (d = 0.69; 40.4% decline) and fatigue (d = −0.33; 37.2% decline) worsened over one year. Cognitive impairment, depression/anxiety, fatigue and apathy all correlated with worse quality of life.Conclusion Nearly half of participants >2 years post-event exhibited psychological difficulties, which impact long-term quality of life. Stroke is a chronic condition requiring long-term psychological support.Competing Interest StatementND is a developer of the Oxford Cognitive Screen but does not receive any remuneration from its use. TJQ chairs the DMC for a vascular cognitive impairment trial supported by NovoNordisk; TJQ has provided outcomes assessment and advisory board input for trials in cognition for Novartis, NovoNordisk.Clinical Protocols https://journals.sagepub.com/doi/full/10.1177/23969873211046120 Funding StatementThis study was funded by a Priority Programme Grant from the Stroke Association (SA PPA 18/100032). ND (Advanced Fellowship NIHR302224) is funded by the National Institute for Health Research (NIHR). The project was supported by the National Institute for Health Research (NIHR) Oxford Health BRC. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR, NHS or the UK Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Health Research Authority - South Central Berkshire Research Ethics Committee approved this study (REC Reference: 19/SC/0520)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available online at osf.io/y2mev https://osf.io/y2mev AESApathy Evaluation ScaleCSICaregiver Strain IndexHADSHospital Anxiety and Depression ScaleICECAPICEpop Capability Measure for AdultsIQ-CODEInformant Questionnaire on Cognitive Decline in the ElderlyEQ-5D-5LEuroQol 5-Dimesions 5-LevelsFDRFalse Discovery RateFSSFatigue Severity ScaleGDSGeriatric Depression ScaleMCIDMinimal Clinically Important DifferenceMoCAMontreal Cognitive AssessmentMMSEMini-Mental State ExaminationNIHSSNational Institutes of Health Stroke ScaleOCSOxford Cognitive ScreenSCISleep Condition IndicatorSF-SISStroke Impact Scale Short FormWHOQOL-BREFWorld Health Organization Quality of Life Brief Version